Sera Prognostics (SERA) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary
Event summary combining transcript, slides, and related documents.
H.C. Wainwright 26th Annual Global Investment Conference 2024 summary
3 Feb, 2026Key challenges in pregnancy care
Preterm birth affects 1 in 10 pregnancies in the US, with significant disparities among populations and a $25 billion annual cost burden.
Black women experience double the rate of preterm birth compared to Caucasian women.
Most preterm births occur without warning, making early detection critical.
Innovation and clinical solution
Developed a proteomics-based PreTRM test to identify risk of spontaneous preterm birth in healthy, asymptomatic singleton pregnancies.
Test is administered between weeks 18-21, aligning with routine second trimester care.
Intervention bundle includes low-dose aspirin, vaginal progesterone, and structured nurse calls.
Clinical and economic impact
AVERT study showed a week-long reduction in neonatal hospital stay and 18% reduction in severe complications.
For the earliest preterm births, NICU stays were reduced by nearly a month, with significant cost savings.
PRIME pivotal trial was halted early for success, confirming health and economic benefits.
Elevance modeling showed $1,600 in cost savings per member tested, with results realized within six months.
Latest events from Sera Prognostics
- PRIME study validated efficacy, commercial expansion advanced, and cash runway secured.SERA
Q4 202518 Mar 2026 - PreTRM enables early, validated prediction of preterm birth, reducing NICU admissions and costs.SERA
Corporate presentation18 Mar 2026 - Strong clinical results drive rapid US expansion and set the stage for European market entry.SERA
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - PreTRM enables early, accurate preterm birth risk prediction, improving outcomes and reducing costs.SERA
Corporate presentation2 Mar 2026 - Net loss narrowed 21% as cash runway extends to 2027 and pivotal PreTRM studies advance.SERA
Q2 20242 Feb 2026 - Genomic and proteomic innovations are reshaping newborn care, with adoption set to accelerate.SERA
UBS Genomic Medicine Conference2 Feb 2026 - Q3 revenue fell and losses widened, but PRIME study and new initiatives aim to drive growth.SERA
Q3 202416 Jan 2026 - Pivotal trials validate a cost-saving preterm birth risk test, poised for broad adoption.SERA
Piper Sandler 36th Annual Healthcare Conference11 Jan 2026 - Proteomics-based test enables early intervention, reducing preterm birth complications and costs.SERA
43rd Annual J.P. Morgan Healthcare Conference 202510 Jan 2026